CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
Proving a technology works and proving it can win a share of a crowded market are two different things. CRISPR Therapeutics (NASDAQ: CRSP) will soon be put to the test on both. The biotech expects to report data for two clinical trial readouts in the coming months. For the stock to do well, the market will need to be impressed by the data, not merely have its (high) expectations confirmed. Here's what to expect. Image source: The Motley Fool. Continue reading